Total Funding
42
49
Total FundingGrant raised
Growth Score
-18 pts
Heat Score
-13 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
50135
Cidara Therapeutics develops targeted immunotherapies aimed at improving treatment outcomes for patients with serious diseases.
Preetam Shah: Chief Financial Officer & Chief Business OfficerPast Role: BrainStorm Cell Therapeutics, EVP, Chief Financial Officer and Treasurer
Ken Bartizal: Chief Development Officer
About the Company
Cidara Therapeutics develops targeted immunotherapies aimed at improving treatment outcomes for patients with serious diseases. The company utilizes its Cloudbreak platform to create single-molecule cocktails that combine small molecules and peptides with human antibody fragments. These drug-Fc conjugate immunotherapies are designed to target
specific disease mechanisms while simultaneously activating the immune system. Cidara focuses on applications in infectious diseases, such as influenza, as well as in immuno-oncology. Its approach integrates molecular targeting with immune engagement to address challenging medical conditions. The company continues to advance its pipeline of therapies through research and development initiatives.
